NICE recommends combination treatment for patients with multiple myeloma

pharmafile | December 24, 2021 | News story | Medical Communications  

NICE has recommended the use of Darzalex (daratumumab) in combination with Velcade (bortezomib), thalidomide and dexamethasone (DVTd) as induction and consolidation treatment for untreated multiple myeloma in adults, when an autologous stem cell transplant (ASCT) is suitable.

This positive Final Appraisal Document (FAD) means that eligible patients in England and Wales will be able to access DVTd on the NHS, in line with the rest of the UK.

As it stands, around 24,000 people are living with multiple myeloma in the UK. The decision to recommend DVTd as a front-line treatment has the potential to offer eligible NHS patients longer periods of remission and improved progression-free survival versus bortezomib, thalidomide and dexamethasone (VTd) alone, while potentially delaying complications associated with multiple myeloma.

The NICE recommendation is based on data from the Phase III CASSIOPEIA study, with a median follow-up of 18.8 months which compared DVTd to standard of care as induction and consolidation therapy in newly diagnosed multiple myeloma patients eligible for ASCT.

“We are delighted that people with multiple myeloma in England and Wales will now be able to access DVTd on the NHS,” said Amanda Cunnington, Director of Health Economics, Market Access, Reimbursement and Health Affairs, Janssen-Cilag Limited.

“Today’s decision means access will now be equal across the UK and we’re proud to have worked collaboratively with stakeholders to achieve this outcome. Importantly, our work in multiple myeloma doesn’t stop here, and we remain committed to furthering advances in science and evolving innovation in blood cancers.”

Lina Adams

Related Content

No items found

Latest content